JillaryJill
08-06-2015, 09:08 AM
I was patient #8 in this trial. Very positive report.
Phase I Trial analyses shows safety and positive immune response data
SEATTLE, June 23, 2015 /PRNewswire/ – TapImmune Inc. (TPIV) is pleased to report the completion of data analysis from patients treated in a Phase I clinical trial. In this Phase 1 trial conducted at the Mayo Clinic in Rochester, MN, women diagnosed with HER2+ breast... cancer (Stages II-III) that had completed standard treatment (i.e. surgery, chemotherapy, and Herceptin™) at least 90 days prior to enrollment were declared disease free and were treated with a multi-peptide HER2/neu vaccine.
Twenty-two subjects (age 33 to 69 years) were enrolled. Patients were injected six times over six months with the multi-peptide vaccine and were monitored for toxicity during each visit. Twenty-one patients completed all 6 vaccination cycles.
Vaccine induced T-cell immunity was observed in 19 out of 20 evaluable patients.
Phase I Trial analyses shows safety and positive immune response data
SEATTLE, June 23, 2015 /PRNewswire/ – TapImmune Inc. (TPIV) is pleased to report the completion of data analysis from patients treated in a Phase I clinical trial. In this Phase 1 trial conducted at the Mayo Clinic in Rochester, MN, women diagnosed with HER2+ breast... cancer (Stages II-III) that had completed standard treatment (i.e. surgery, chemotherapy, and Herceptin™) at least 90 days prior to enrollment were declared disease free and were treated with a multi-peptide HER2/neu vaccine.
Twenty-two subjects (age 33 to 69 years) were enrolled. Patients were injected six times over six months with the multi-peptide vaccine and were monitored for toxicity during each visit. Twenty-one patients completed all 6 vaccination cycles.
Vaccine induced T-cell immunity was observed in 19 out of 20 evaluable patients.